Synthetic Biologics, Inc. (NYSEMKT:SYN)

CAPS Rating: 1 out of 5

A development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.

Results 1 - 10 of 10

Recs

0
Member Avatar pchop12316 (81.30) Submitted: 7/31/2015 10:36:39 AM : Underperform Start Price: $3.21 SYN Score: -0.97

likely to keep dropping in value

Recs

1
Member Avatar zzlangerhans (99.69) Submitted: 7/23/2015 12:39:07 PM : Underperform Start Price: $3.31 SYN Score: +1.39

Synthetic Biologics has done vastly better than I ever imagined when I green thumbed them last year, but I'm going to bet the run is out of gas. MRI topline data from the phase II trial of Trimesta in MS has never materialized despite being promised in the first half of 2015, and data from the phase IIa trial of SYN-004 promised for this month still hasn't appeared. Meanwhile, the company just priced a huge secondary offering well below market at 3. True to its recent nature, the street has ignored these red flags and is pushing the share price back up towards the pre-financing high. My style is to ignore momentum and respect the red flags, which loses money in the short term but generally saves me from tears afterwards.

Recs

0
Member Avatar Allstar13913 (99.85) Submitted: 1/24/2015 11:20:58 PM : Underperform Start Price: $1.52 SYN Score: -110.05

This is a reup of a former Red thumb.
-----
Crap pharma. Has not been profitable in 10 years.

Recs

0
Member Avatar QUINT27 (< 20) Submitted: 2/21/2014 7:15:16 AM : Outperform Start Price: $2.73 SYN Score: +4.63

Trimesta results in April will double stock value.

Recs

2
Member Avatar vpdjuric (< 20) Submitted: 1/21/2011 3:02:18 AM : Outperform Start Price: $1.45 SYN Score: +60.03

I have to respectfully disagree with zz below. Zinth is definitely not a cure for Alzheimer's, and it is not advertised as such. It is a prescription medical food meant to slow cognitive degradation seen in Alzheimer's and similar diseases. The hypothesis is that since there is a significant correlation between zinc deficiency and degradation of cognitive function, taking zinc supplements may slow cognitive deterioration. Zinth is comprised of zinc and cysteine, and both components are generally regarded as safe, which reduces the number of hurdles Adeona has to overcome to get it to market. Zinth's differentiation from standard zinc supplements is its ease of digestion, whereas common zinc supplements commonly have side effects of indigestion, nausea, and heartburn. Anecdotal results have been positive so far:

http://www.crainsdetroit.com/article/20110102/SUB01/301029993/alzheimers-trial-may-win-deal-for-adeona-supplement-interests-drug-firms#

Beyond Zinth, they are also in various stages of testing 4 other drugs for drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis, a couple of which have blockbuster potential. The management team, led by Dr. Kuo, is stellar, and insiders own 47% of the company. Recently, they added Dr. Anand Prasad to the team, a pioneer in zinc research.

Adeona has already received term sheets for Zinth from potential pharma partners, but nothing has been announced yet. The final data from the Zinc trials will be announced in March, although a partnership may come before then. Kuo has announced that Adeona will hold an investor day on February 8th, during which he will discuss plans for Zinth. If a partnership deal has been signed, that would probably be the day he announced it...

Recs

0
Member Avatar staraman (< 20) Submitted: 9/25/2010 11:36:28 AM : Outperform Start Price: $0.81 SYN Score: +216.17

AEN has formed strong support at around 80 cents. The chart looks good from here and there some catalysts coming in 2011

Recs

0
Member Avatar schrld (< 20) Submitted: 10/30/2007 7:18:45 PM : Outperform Start Price: $6.12 SYN Score: -89.92

this co is incredibly overlooked. It is less than 6 months from having a drg on the market and has a full pipeline. At a cap of only 100million and a float of only 5 million! this stock could have a powerful explosion as their story unfolds and th market becomes aware of them.

Recs

0
Member Avatar SPECTRE2147 (73.92) Submitted: 10/25/2007 10:17:16 AM : Outperform Start Price: $6.92 SYN Score: -97.89

GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOD

Recs

0
Member Avatar samsung2008 (22.25) Submitted: 8/18/2007 12:03:34 AM : Outperform Start Price: $6.10 SYN Score: -99.13

This stock will explode up one day, maybe several days, maybe for months...when the right news hits. News not to far away.

This stock could hold up well in down turns and I expect if Gen. Market conditions improve to the upside, PP could do very very well.

Good products in clinical testing, but market not to far away.

Recs

0
Member Avatar dcuenin (< 20) Submitted: 5/25/2007 6:31:13 AM : Outperform Start Price: $4.07 SYN Score: -67.62

blabla

Results 1 - 10 of 10

Featured Broker Partners


Advertisement